Purepac cefadroxil
Executive Summary
Approved Jan. 5, Purepac's cefadroxil 500 mg caps will be available soon, the company said. Purepac's parent company, Kalipharma, filed a suit in July seeking a declaratory judgment that Bristol's cefadroxil patent is invalid. Purepac received the second cefadroxil ANDA approval following Zenith's in March 1987. Bristol took Zenith to court for patent infringement and the claim was dropped after a consent order was handed down ("The Pink Sheet" June 1, 1987 "In Brief"). Zenith said it is not marketing cefadroxil.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.